Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors
- Bioorg Med Chem Lett. 2022 Aug 15;70:128805. doi: 10.1016/j.bmcl.2022.128805.
- 1. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China.
- 2. State Key Laboratory Breeding Base-Hebei Province Key Laboratory of Molecular Chemistry for Drug, Hebei University of Science and Technology, Shijiazhuang, PR China.
- 3. 3D BioOptima Co,. Ltd., Suzhou 215104, PR China.
- 4. State Key Laboratory Breeding Base-Hebei Province Key Laboratory of Molecular Chemistry for Drug, Hebei University of Science and Technology, Shijiazhuang, PR China. Electronic address: [email protected].
- 5. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China. Electronic address: [email protected].
The pharmacological inhibition of soluble Epoxide Hydrolase (sEH) was shown to reduce inflammation and pain. Herein, we described a series of newly synthesized sEH inhibitors with the trident-shaped skeleton. Intensive structural modifications led to the identification of compound B15 as a potent sEH inhibitor with an IC50 value of 0.03 ± 0.01 nM. Furthermore, compound B15 showed satisfactory metabolic stability in human liver microsomes with a half-time of 197 min. In carrageenan-induced inflammatory pain rat model, compound B15 exhibited a better therapeutic effect compared to t-AUCB and Celecoxib, which demonstrated the proof of potential as anti-inflammatory agents for pain relief.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Epoxide HydrolaseResearch Areas: Inflammation/Immunology